DARE — Dare Bioscience Balance Sheet
0.000.00%
Last trade - 00:00- $47.21m
- $36.74m
- $2.81m
Annual balance sheet for Dare Bioscience, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 4.78 | 4.67 | 51.7 | 34.7 | 10.5 |
| Net Total Receivables | 0.555 | 0.46 | 1.15 | 1.7 | 0.949 |
| Prepaid Expenses | |||||
| Total Current Assets | 6.44 | 6.98 | 55.3 | 43 | 17.5 |
| Net Property, Plant And Equipment | 0.552 | 0.277 | 0.243 | 0.523 | 1.98 |
| Other Long Term Assets | |||||
| Total Assets | 7.44 | 7.55 | 55.8 | 43.8 | 21.3 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 5.61 | 7.66 | 16.1 | 31.6 | 20.5 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 7 | 8.7 | 17.1 | 32.7 | 26.3 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 0.441 | -1.15 | 38.8 | 11.1 | -5.05 |
| Total Liabilities & Shareholders' Equity | 7.44 | 7.55 | 55.8 | 43.8 | 21.3 |
| Total Common Shares Outstanding |